Shopping Cart
- Remove All
- Your shopping cart is currently empty
LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $797 | 7-10 days | |
50 mg | $1,280 | 7-10 days | |
100 mg | $1,940 | 7-10 days |
Description | LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM). |
Targets&IC50 | SDF-1α-CXCR4:49.5 pM (ki), SDF-1α-CXCR4:79.7 pM |
In vitro | LY2510924 inhibits SDF-1–induced cell migration (IC50: 0.26 nM) and inhibits SDF-1/CXCR4-mediated intracellular signaling, in human lymphoma U937 cells expressing endogenous CXCR4. LY2510924 also inhibits SDF-1–induced GTP binding (Kb: 0.38 nM). LY2510924 specifically blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM). LY2510924 displays a concentration-dependent inhibition of SDF-1–stimulated phospho-ERK and phospho-Akt in tumor cells. Biochemical and cellular analyses reveal that LY2510924 has no apparent agonist activity[1]. LY2510924 chiefly inhibits the proliferation of AML cells with little induction of cell death and reduces protection against chemotherapy by stromal cells[2]. |
Molecular Weight | 1189.45 |
Formula | C62H88N14O10 |
Cas No. | 1088715-84-7 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (105.09 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.